June 4, 2019

To	To
Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sirs,

Sub: Clarification on media report "Aurobindo Pharma slips 5% after detailed USFDA observations to unit 3".
Ref : Email dated June 4, 2019 from BSE Ltd.

This has reference to your above cited email seeking clarification on the subject matter.

With reference to the above, we inform you that the United States Food and Drug Administration (US FDA / Regulator) had conducted an inspection at our Company's Unit III, a formulation manufacturing facility located at Bachupally, Hyderabad from 13th May 2019 to 24th May 2019. In this regard, the Company has received a 'Form 483' with ten observations. None of the observations are repetitive and are more procedural in nature. The Company will be responding to the US FDA within the stipulated time. The Form 483 will not have an impact on existing business of this facility.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B.Adi Reddy
Company Secretary